University of Bonn

University of Bonn

University of Bonn

Overview
Date Founded

1818

Headquarters

Regina-Pacis-Weg 3,Bonn, Nordrhein-Westfalen 53113

Employees (Worldwide)

5,001 - 10K

Company Description

The University of Bonn is a public research university located in Bonn, Germany. It was founded in its present form as the Rhein University on 18 October 1818 by Frederick William III, as the linear successor of the Kurkölnische Akademie Bonn (English: Academy of the Prince-elector of Cologne) which was founded in 1777. The University of Bonn offers a large number of undergraduate and graduate programs in a range of subjects and has 544 professors and 32,500 students. Its library holds more than five million volumes. Among its notable alumni and faculty are seven Nobel Laureates, three Fields Medalist, twelve Gottfried Wilhelm Leibniz Prize winners, Prince Albert, Pope Benedict XVI, Frederick III, Karl Marx, Heinrich Heine, Friedrich Nietzsche, Konrad Adenauer, and Joseph Schumpeter. The Times Higher Education World University Rankings 2016 and the Academic Ranking of World Universities 2015 ranked the University of Bonn as one of the 100 best universities in the world.

Executives & Employees

Head of Computer Science Department

Director-Institute of Experimental Hematology

Professor

Professor

Professor

Lecturer

Senior Lecturer

Faculty Member

Associate Professor

Assistant Professor

Board of Directors

Secretary & Chief Human Resources Officer at Kühne + Nagel International AG

Founder at Earn/Bitnet

Distinguished Alumni
Cole R. Bader is now Managing Director & Co-Head, Mergers & Acquisitions at Stifel, Nicolaus & Co., Inc.
Stephen T. H. Ng is now Executive Chairman of the Board, Managing Director at The Wharf (Holdings) Ltd.
Martin H. Richenhagen is now Chairman of the Board, President, Chief Executive Officer at AGCO Corp.
Paths to University of Bonn
Potential Connections via
Relationship Science
You
University of Bonn
Clients

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by University of Bonn. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of University of Bonn's profile does not indicate a business or promotional relationship of any kind between RelSci and University of Bonn.